Details of the Drug Combination

General Information of Drug Combination (ID: DC578PJ)

Drug Combination Name
CP-868596 LY3023414
Indication
Disease Entry Status REF
Hodgkin lymphoma Investigative [1]
Component Drugs CP-868596   DMZIM37 LY3023414   DMD9KYF
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: L-1236
Zero Interaction Potency (ZIP) Score: 109.124
Bliss Independence Score: 107.848
Loewe Additivity Score: 11.038
LHighest Single Agent (HSA) Score: 3.668

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of CP-868596
Disease Entry ICD 11 Status REF
Gastrointestinal cancer 2C11 Phase 3 [2]
Gastrointestinal stromal tumour 2B5B Phase 3 [3]
Acute myelogenous leukaemia 2A41 Phase 2 [4]
Acute myeloid leukaemia 2A60 Phase 2 [3]
Malignant glioma 2A00.0 Phase 1 [4]
CP-868596 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Platelet-derived growth factor receptor alpha (PDGFRA) TT8FYO9 PGFRA_HUMAN Modulator [6]
Proto-oncogene c-Src (SRC) TT6PKBN SRC_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Indication(s) of LY3023414
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Phase 2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
LY3023414 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Serine/threonine-protein kinase mTOR (mTOR) TTCJG29 MTOR_HUMAN Modulator [7]
PI3-kinase alpha (PIK3CA) TTEUNMR PK3CA_HUMAN Modulator [7]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7882).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 ClinicalTrials.gov (NCT02549989) Study of LY3023414 for the Treatment of Recurrent.
6 The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9.
7 Company report (Lilly)